Analyst Price Targets — SNDX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 12, 2026 11:07 am | Brad Canino | Guggenheim | $31.00 | $17.91 | TheFly | Syndax price target lowered to $31 from $34 at Guggenheim |
| June 3, 2026 10:52 am | Andres Maldonado | H.C. Wainwright | $40.00 | $18.39 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX) |
| May 4, 2026 10:48 am | — | Stifel Nicolaus | $46.00 | $19.11 | TheFly | Syndax price target raised to $46 from $45 at Stifel |
| May 1, 2026 9:39 am | — | Barclays | $37.00 | $21.43 | TheFly | Syndax price target raised to $37 from $35 at Barclays |
| February 27, 2026 5:03 pm | Stephen Willey | Stifel Nicolaus | $45.00 | $21.71 | StreetInsider | Syndax Pharmaceuticals (SNDX) PT Raised to $45 at Stifel |
| November 24, 2025 11:31 am | — | Barclays | $35.00 | $17.44 | TheFly | Syndax price target raised to $35 from $22 at Barclays |
| November 4, 2025 12:36 pm | — | UBS | $38.00 | $13.76 | TheFly | Syndax price target raised to $38 from $35 at UBS |
| November 4, 2025 10:09 am | Peter Lawson | Barclays | $22.00 | $13.76 | TheFly | Syndax price target raised to $22 from $19 at Barclays |
| September 10, 2025 9:10 am | — | Stifel Nicolaus | $44.00 | $15.73 | TheFly | Syndax resumed with a Buy at Stifel |
| July 15, 2025 10:51 am | David Dai | UBS | $35.00 | $9.80 | TheFly | Syndax price target lowered to $35 from $37 at UBS |
Latest News for SNDX
Does Syndax Pharmaceuticals (SNDX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies Transcript
Syndax Pharmaceuticals NASDAQ: SNDX used a company R&D event to outline expansion plans for its approved medicines Revuforj and Niktimvo while introducing two pipeline assets aimed at non-small cell lung cancer and myelofibrosis.
The consensus price target hints at a 70.4% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SNDX.
U.S. House Trading
No House trades found for SNDX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.